QTRX - Quanterix Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
34.00
-1.20 (-3.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close35.20
Open35.36
Bid0.00 x 900
Ask0.00 x 800
Day's Range32.77 - 35.49
52 Week Range13.00 - 36.13
Volume220,074
Avg. Volume154,149
Market Cap921.274M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.52
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.67
Trade prices are not sourced from all markets
  • Did Quanterix's (NASDAQ:QTRX) Share Price Deserve to Gain 66%?
    Simply Wall St.18 days ago

    Did Quanterix's (NASDAQ:QTRX) Share Price Deserve to Gain 66%?

    If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...

  • Business Wire20 days ago

    Quanterix Raises $49.7 Million and Announces Introduction of Latest Model Simoa HD-X Analyzer at BIO 2019 International Convention

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, announced that it issued approximately 2.2 million shares of common stock last week, raising $49.7 million in gross proceeds. Additionally, Quanterix will unveil its Simoa HD-X Analyzer™, at the BIO International Convention, in Philadelphia, during a presentation by its Chairman and CEO, Kevin Hrusovsky, taking place June 5 at 10:45 a.m., EDT, in Theater 3. Quanterix is re-engineering ultra-sensitivity with the launch of the HD-X, its latest fully automated Simoa bead-based immunoassay instrument model.

  • Quanterix Expands Headquarters to New, State-of-the-Art Facility in Billerica, Mass. as Demand Continues to Grow for its Disruptive Simoa Platforms
    Business Wire26 days ago

    Quanterix Expands Headquarters to New, State-of-the-Art Facility in Billerica, Mass. as Demand Continues to Grow for its Disruptive Simoa Platforms

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the relocation of its headquarters to a brand new, state-of-the-art facility in Billerica, Mass. Brought on by Quanterix’ rapid growth, the move will allow the Company to unite its CLIA-certified laboratory with its expanding workforce to accelerate entry into pharmaceutical drug services and further increase its impact on the transformation of precision healthcare. “We experienced considerable success in our former facilities, launching several new biomarker technologies that are beginning to disrupt drug development and drug approval methodologies, acquiring Aushon to accelerate our entry into Biopharma services and leading a successful public offering in December 2017,” said Kevin Hrusovsky, Chairman and CEO, Quanterix.

  • Business Wirelast month

    Quanterix Announces $50,000 in Grants to Support Promising Oncology Research

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a call for proposals for a new Accelerator Grant Program. Designed to help facilitate breakthroughs in science and medicine, this year’s Accelerator Grant Program will award up to $50,000 toward the cost of research in Quanterix’ Accelerator Lab to help advance the most exciting biomarker research using Quanterix’ ultrasensitive Simoa technology.

  • Here’s What Hedge Funds Think About Quanterix Corporation (QTRX)
    Insider Monkeylast month

    Here’s What Hedge Funds Think About Quanterix Corporation (QTRX)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • Quanterix Corporation (QTRX) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Quanterix Corporation (QTRX) Q1 2019 Earnings Call Transcript

    QTRX earnings call for the period ending March 31, 2019.

  • Business Wire2 months ago

    Quanterix Corporation Releases Operating Results for First Quarter 2019

    64% Q1 revenue growth and 650 bps gross margin improvement

  • Business Wire2 months ago

    Quanterix’ Simoa Technology Powers More Than 85 Percent of Neurofilament Light Biomarker Research to be Unveiled at American Academy of Neurology Annual Meeting

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology is the driving force behind 36 of the 42 – nearly 86 percent – Nf-L abstracts being presented at the American Academy of Neurology (AAN)’s Annual Meeting, taking place from May 4-10, 2019 in Philadelphia, PA. This year’s program represents a nearly four-fold increase in Nf-L research compared to last year, reinforcing the marker’s mounting value as a key indicator of neurodegenerative disease onset and progression. “As the use cases for Nf-L grow, evidenced by the growing body of research presented at AAN, we believe that this biomarker is truly one of the most promising biomarkers for brain health with the power to completely transform the way diseases like Alzheimer’s, Multiple Sclerosis, Parkinson’s, and even brain injuries are diagnosed and treated,” said Kevin Hrusovsky, Chairman and CEO of Quanterix.

  • Business Wire2 months ago

    Quanterix to Release First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for first quarter 2019 after the close of trading on Thursday, May 9, 2019. Company management will host a conference call at 4:30 p.m., EDT to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chief Executive Officer, President and Chairman, Quanterix.

  • Will Quanterix Corporation's (NASDAQ:QTRX) Earnings Grow In The Next Couple Of Years?
    Simply Wall St.3 months ago

    Will Quanterix Corporation's (NASDAQ:QTRX) Earnings Grow In The Next Couple Of Years?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The latest earnings release Quanterix Corporation's (NASDAQ:QTRX) announced in December 2018 showed...

  • Business Wire3 months ago

    Quanterix Appoints Amol Chaubal as Chief Financial Officer

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has named Amol Chaubal to the position of Chief Financial Officer (CFO), effective April 12, 2019. Amol replaces Joseph Driscoll, who is stepping down from his current role as CFO. “Our company’s accelerated growth over the past several years, combined with the magnitude of the opportunity we have to transform healthcare with digital biomarkers requires us to scale our executive team accordingly with top talent,” said Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix.

  • GuruFocus.com3 months ago

    Quanterix Corp (QTRX) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Quanterix Corp is a life science company. Warning! GuruFocus has detected 4 Warning Sign with QTRX. For the last quarter Quanterix Corp reported a revenue of $10.9 million, compared with the revenue of $6.59 million during the same period a year ago.

  • Quanterix Corporation (QTRX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Quanterix Corporation (QTRX) Q4 2018 Earnings Conference Call Transcript

    QTRX earnings call for the period ending December 31, 2018.

  • Business Wire4 months ago

    Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2018

    65% Q4 revenue growth; 65% full year growth

  • Business Wire4 months ago

    Quanterix to Release Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Thursday, March 7, 2019

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for fourth quarter and full year 2018 after the close of trading on Thursday, March 7, 2019. Company management will host a conference call at 4:30 p.m., ET to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chief Executive Officer, President and Chairman, Quanterix.

  • Business Wire4 months ago

    Quanterix to Present at Multiple Upcoming Healthcare Conferences

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will be presenting and hosting one-on-one meetings with investors at multiple high-profile healthcare conferences. Hrusovsky will present at the eighth Annual Leerink Partners Global Healthcare Conference on Friday, March 1, 2019 at 9:30 a.m., EST, at the Lotte New York Palace in New York City, NY.

  • Could a blood test predict Alzheimer's disease 16 years before symptoms?
    American City Business Journals4 months ago

    Could a blood test predict Alzheimer's disease 16 years before symptoms?

    In a 405-person clinical trial, Quanterix's technology was able to detect upticks on a potential biomarker as much as 16 years before the participant began showing symptoms.

  • Business Wire5 months ago

    Quanterix to Present at 21st Annual Needham Growth Conference

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will be presenting at the 21st Annual Needham Growth Conference, on Jan. 16, at 4:10 p.m., EST, at the Lotte New York Palace Hotel, New York City. To access the live webcast of Quanterix’ presentations, please visit the News & Events page within the Investors section of the Quanterix website at www.quanterix.com. Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health.

  • Business Wire5 months ago

    Quanterix Extends Oncology Footprint with Accelerated Launch of Next Gen SP-X™ Platform and CorPlex™ Validated 10-Plex

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the much-anticipated full launch of its Simoa SP-X Imaging and Detection System, 10-Plex Simoa CorPlex Cytokine Panel, and broad menu of additional multiplex panels. The new instrument platform and highly validated CorPlex assays promise to revolutionize oncology research and drug development. The progress made since the early access program was initiated in early November 2018 with select industry leaders has validated the performance and promise of the technology, resulting in an accelerated timeline for full launch.

  • Business Wire6 months ago

    Quanterix Marks One-Year Anniversary of IPO with Key Milestones Accelerating Healthcare Disruption Ahead of Presentation at the 37th Annual J.P. Morgan Healthcare Conference

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, is marking a little over one year since becoming a public company with significant milestones on its path toward revolutionizing healthcare. Quanterix’ Chief Executive Officer, President and Chairman will highlight these achievements and future plans during a presentation at the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, Jan. 9, 2019 at 2 p.m., PST. Since going public and listing on the Nasdaq on Dec. 7, 2017 – in one of the most successful IPOs of its kind in recent years – Quanterix has continued to achieve accelerated double-digit, year-over-year revenue growth in each full quarter since the IPO.

  • Have Insiders Been Selling Quanterix Corporation (NASDAQ:QTRX) Shares This Year?
    Simply Wall St.6 months ago

    Have Insiders Been Selling Quanterix Corporation (NASDAQ:QTRX) Shares This Year?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...

  • Facing headwinds, medtech sector won't be left to its own devices
    American City Business Journals6 months ago

    Facing headwinds, medtech sector won't be left to its own devices

    Here’s a look at three key issues facing the medical device sector — and the Massachusetts health care economy at large — in 2019.

  • Business Wire7 months ago

    Quanterix to Present at the Evercore ISI HealthCONx Conference

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Evercore ISI HealthCONx Conference on Thursday, Nov. 29, 2018 at 11:45 a.m., EST at the Boston Harbor Hotel in Boston. To access the live webcast of Quanterix’ presentation, please visit the News & Events page within the Investors section of the Quanterix website at www.quanterix.com. Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health.

  • GlobeNewswire7 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Okta, One Horizon Group, Vivopower International Plc, PetIQ, Quanterix, and Eidos Therapeutics — New Research Emphasizes Economic Growth

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire7 months ago

    Quanterix to Present at the Canaccord Genuity Medical Technologies & Diagnostic Forum

    Quanterix Corporation (QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Canaccord Genuity Medical Technologies & Diagnostic Forum, on Thursday, Nov. 15, 2018 at 10 a.m., EST in New York City. To access the live webcast of Quanterix’ presentation, please visit the News & Events page within the Investors section of the Quanterix website at www.quanterix.com. Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health.